Gyre Therapeutics (GYRE) Non-Current Debt (2010 - 2014)
Gyre Therapeutics (GYRE) posted quarterly Non-Current Debt of $142000.0 for Q1 2014, down 84.53% year-over-year from $918000.0 in Q1 2013, and down 49.82% quarter-over-quarter from $283000.0 in Q4 2013.
Gyre Therapeutics (GYRE) Non-Current Debt (2010 - 2014) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Non-Current Debt for 5 consecutive years, with $142000.0 the latest figure, recorded in Q1 2014.
- In Q1 2014, Non-Current Debt fell 84.53% year-over-year to $142000.0; the TTM figure through Mar 2014 stood at $142000.0 (down 84.53% YoY), while the FY2013 annual figure was $283000.0, down 75.09% from the prior year.
- Non-Current Debt fell to $142000.0 in Q1 2014 per GYRE's latest filing, from $283000.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $2.4 million in Q2 2011 and bottomed at $142000.0 in Q1 2014.
- Historically, Non-Current Debt has averaged $1.3 million across 5 years, with a median of $1.3 million in 2010.
- Annual changes were most pronounced in 2011 — Non-Current Debt jumped 47.22% — and 2014, when it plunged 84.53%.
- Gyre Therapeutics' Non-Current Debt stood at $1.3 million in 2010, then surged by 47.22% to $2.0 million in 2011, then slumped by 42.8% to $1.1 million in 2012, then plunged by 75.09% to $283000.0 in 2013, then sank by 49.82% to $142000.0 in 2014.
- Business Quant data shows GYRE's Non-Current Debt at $142000.0 in Q1 2014, $283000.0 in Q4 2013, and $478000.0 in Q3 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2014 | 142,000.00 |
| Dec 31, 2013 | 283,000.00 |
| Sep 30, 2013 | 478,000.00 |
| Jun 30, 2013 | 699,000.00 |
| Mar 31, 2013 | 918,000.00 |
| Dec 31, 2012 | 1.14 Mn |
| Sep 30, 2012 | 1.35 Mn |
| Jun 30, 2012 | 1.56 Mn |
| Mar 31, 2012 | 1.78 Mn |
| Dec 31, 2011 | 1.99 Mn |
| Sep 30, 2011 | 2.20 Mn |
| Jun 30, 2011 | 2.44 Mn |
| Dec 31, 2010 | 1.35 Mn |